Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Kinzalmono er større end risiciene ved behandling af essentiel hypertension hos voksne.
The Committee for Medicinal Products for Human Use (CHMP) decided that Kinzalmono’ s benefits are greater than its risks for the treatment of essential hypertension in adults.